Weekly Genomic Health, Inc. (NASDAQ:GHDX) Ratings on May 16, 2018

May 16, 2018 - By Carolyn Hewitt

Genomic Health, Inc. (NASDAQ:GHDX) Corporate Logo
During Q4 2017 the big money sentiment decreased to 1.13. That’s change of 1.19, from 2017Q3’s 2.32. 18 investors sold all, 35 reduced holdings as Genomic Health, Inc. ratio is negative. 42 increased positions while 18 funds took positions. Funds hold 31.21 million shares thus 1.14% more from 2017Q3’s 30.86 million shares.
Nordea Ab owns 80,713 shs for 0.01% of their capital. Blackrock owns 0% invested in Genomic Health, Inc. (NASDAQ:GHDX) for 1.95 million shs. Pub Employees Retirement Association Of Colorado has invested 0% in Genomic Health, Inc. (NASDAQ:GHDX). Geode Management Lc, a Massachusetts-based fund reported 179,465 shs. 140,123 are owned by Retail Bank Of America De. Pictet Asset Ltd holds 0.01% in Genomic Health, Inc. (NASDAQ:GHDX) or 89,600 shs. Pdts Ptnrs Ltd Co, New York-based fund reported 14,127 shs. Alliancebernstein L P accumulated 0% or 37,885 shs. First Manhattan reported 110,900 shs. The Florida-based Eagle Asset Management has invested 0.06% in Genomic Health, Inc. (NASDAQ:GHDX). California State Teachers Retirement reported 31,137 shs stake. Amer Century, Missouri-based fund reported 194,503 shs. Strs Ohio reported 25,500 shs. State Farm Mutual Automobile Insur holds 0.02% or 350,741 shs in its capital. The Pennsylvania-based Pnc Fincl Svcs Inc has invested 0% in Genomic Health, Inc. (NASDAQ:GHDX).

Genomic Health, Inc. had 16 sales and 0 insider buys since December 12, 2017. This’s net activity of $4.15 million. Cole G Bradley sold $164,474 worth of Genomic Health, Inc. (NASDAQ:GHDX) or 5,000 shs on Tuesday, February 20. Popovits Kimberly J had sold 20,000 shs worth $630,000. Vaughn James J also sold $48,653 worth of Genomic Health, Inc. (NASDAQ:GHDX) shs. Leber Laura also sold $111,080 worth of Genomic Health, Inc. (NASDAQ:GHDX) shs. $162,290 worth of Genomic Health, Inc. (NASDAQ:GHDX) was sold by Febbo Phillip G..

Genomic Health, Inc. (NASDAQ:GHDX) Ratings Coverage

In total 8 analysts cover Genomic Health (NASDAQ:GHDX). “Buy” rating has 1, “Sell” are 3, while 4 are “Hold”. 13% are bullish. 9 are the (NASDAQ:GHDX)’s analyst reports since December 13, 2017 according to StockzIntelligence Inc. On Thursday, March 8 the stock of Genomic Health, Inc. (NASDAQ:GHDX) has “Hold” rating given by Piper Jaffray. On Thursday, May 3 Deutsche Bank maintained Genomic Health, Inc. (NASDAQ:GHDX) rating. Deutsche Bank has “Hold” rating and $34 target. The company rating was downgraded by William Blair on Wednesday, December 20. On Tuesday, January 16 the rating was maintained by Canaccord Genuity with “Buy”. On Wednesday, December 13 JP Morgan downgraded the shares of GHDX in report to “Underweight” rating. On Wednesday, December 13 the company was downgraded by J.P. Morgan. In Friday, March 9 report Canaccord Genuity maintained the stock with “Buy” rating. Listed here are Genomic Health, Inc. (NASDAQ:GHDX) PTs and latest ratings.

03/05/2018 Broker: Deutsche Bank Old Rating: Hold New Rating: Hold Old Target: $32 New Target: $34 Maintain
09/03/2018 Broker: Canaccord Genuity Rating: Buy New Target: $40.0 Maintain
08/03/2018 Broker: Piper Jaffray Rating: Hold New Target: $33.0 Maintain
16/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $42.0 Maintain
04/01/2018 Broker: Barclays Capital Rating: Sell New Target: $28.0
20/12/2017 Broker: William Blair Rating: Hold Downgrade
14/12/2017 Broker: Raymond James Rating: Hold
13/12/2017 Broker: J.P. Morgan Rating: Sell New Target: $25.0 Downgrade
13/12/2017 Broker: JP Morgan Old Rating: Neutral New Rating: Underweight Downgrade

GHDX touched $37.81 during the last trading session after $0.19 change.Genomic Health, Inc. is downtrending after having declined 2.07% since May 16, 2017. GHDX has 189,710 volume or 2.39% up from normal. GHDX underperformed the S&P 500 by 13.62%.

Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally.The firm is worth $1.34 billion. It develops and commercializes genomic clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.Last it reported negative earnings. The firm offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and chemotherapy benefit.

More recent Genomic Health, Inc. (NASDAQ:GHDX) news were brought out by Seekingalpha.com, Benzinga.com and Prnewswire.com. The first one has “Genomic Health’s (GHDX) CEO Kimberly Popovits on Q1 2018 Results – Earnings Call Transcript” as a title and was brought out on May 03, 2018. The next is “Benzinga’s Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy’s Revenue Miss, FDA Warns E-Liquid Makers Again” on May 11, 2018. And last was brought out on May 09, 2018, called “Genomic Health to Present at Bank of America Merrill Lynch 2018 Health Care Conference”.

Genomic Health, Inc. (NASDAQ:GHDX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: